Peptide-based agents like [18F]AFP-SWL, [99mTc]-HYNIC-SWL, and [68Ga]DOTA-SD01 have shown specificity for EphA2 in melanoma, non-small cell lung, and breast cancers, but issues with plasma degradation and low tumor uptake have limited their use 22-24. This evidence concerns the gene EPHA2 and breast carcinoma.